$4.89
-0.22 (-4.31%)
Open$5.07
Previous Close$5.11
Day High$5.24
Day Low$4.85
52W High$11.41
52W Low$1.73
Volume—
Avg Volume380.6K
Market Cap163.61M
P/E Ratio—
EPS$-1.79
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-38.7% upside
Current
$4.89
$4.89
Target
$3.00
$3.00
$2.20
$3.00 avg
$3.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |
| Rev Growth | +24.7% | +14.4% | -5.6% |
| Debt/Equity | 0.41 | 0.48 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |